Astria Therapeutics (ATXS) Jefferies Global Healthcare Conference 2025 summary

Strategic focus and pipeline overview

• Focus on developing first-choice therapies for allergic and immunologic diseases, prioritizing efficacy, safety, and low treatment burden.

• Lead asset navenibart targets plasma kallikrein for hereditary angioedema (HAE), currently in phase III with both three- and six-month dosing regimens.

• STAR-0310, an OX40 antagonist for atopic dermatitis, is in phase I with healthy volunteer data expected later this year.

Clinical development and trial design

• Navenibart phase III trial initiated in February, enrolling globally with three active arms and a placebo arm; top-line data expected early 2027.

• Both three- and six-month dosing regimens included in a single pivotal trial, offering flexibility and operational cost savings.

• Adolescents included in phase III without placebo, based on regulatory feedback, to support label expansion.

Efficacy, safety, and market positioning

• Proof-of-concept data for navenibart showed >90% attack rate reduction; phase III aims for 80–90% reduction in both dosing cohorts.

• Long-term extension (ALPHA-SOLAR) data expected mid-year, focusing on sustained efficacy and safety.

• Market research indicates strong physician and patient interest in both dosing regimens, with potential for navenibart to become market leader.